Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Thrombosis Research

Background:

• Aspirin (acetylsalicylic acid) inhibits cyclooxygenase-1 (COX-1) to prevent thrombosis.
• Non-platelet actions of aspirin can limit its antithrombotic efficacy.
• Understanding tissue-specific COX-1 inhibition is crucial for optimizing aspirin therapy.

Purpose of the Study:

• To differentiate the effects of platelet COX-1 inhibition from systemic COX-1 inhibition by aspirin.
• To define the specific eicosanoid profiles affected by aspirin in platelets versus other cardiovascular tissues.
• To elucidate the mechanisms underlying aspirin's variable antithrombotic effects.

Main Methods:

• Utilized platelet-specific COX-1 knockout (KO) mice and global COX-1 KO mice.
• Employed mass spectrometry to analyze eicosanoid production in vitro and in vivo.
• Conducted in vitro and in vivo thrombosis studies.
• Performed Ingenuity Pathway Analysis (IPA) for predictive modeling.

Main Results:

• In vitro, platelet-COX-1-KO and global-COX-1-KO mice showed similar absence of thromboxane A2 (TxA2) and other eicosanoids.
• In vivo, platelet-COX-1-KO mice exhibited distinct eicosanoid profiles, including higher levels of prostacyclin (PGI2) metabolite, compared to controls.
• Aspirin or systemic COX-1 deficiency reduced anti-aggregatory PGI2 and prostaglandin D2 (PGD2) synthesis, predicting increased thrombosis.
• Thrombosis studies confirmed these predictions, demonstrating increased thrombosis with systemic COX-1 inhibition.

Conclusions:

• Established distinct eicosanoid profiles for COX-1 inhibition in platelets versus non-platelet cardiovascular sites.
• Demonstrated that aspirin's systemic inhibition of COX-1 reduces beneficial anti-aggregatory eicosanoids (PGI2, PGD2).
• Explained how aspirin's non-platelet actions can counteract its antithrombotic effects, potentially explaining reduced efficacy with higher doses or combination therapies.